​
​

LENZ Therapeutics Ownership | Who Owns LENZ Therapeutics?

OverviewForecastRevenueFinancialsChart

LENZ Therapeutics Ownership Summary

LENZ Therapeutics is owned by 54.26% institutional investors, and 45.74% retail investors. Galileo - Biotech Innovation Fund S USD is the top mutual fund, with 0.51% of its assets in LENZ Therapeutics shares.

GRPH Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockLENZ Therapeutics54.26%-45.74%
SectorHealthcare Stocks 47.38%7.99%44.63%
IndustryBiotech Stocks 45.43%7.81%46.75%

Institutional Shareholders

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 202364-4.48%31,066,8951.64%541.87%30-6.25%18-
Sep 30, 202367-4.29%30,564,828-2.95%531.69%32-15.79%1820.00%
Jun 30, 20237011.11%31,494,7965.93%561.99%3826.67%15-11.76%
Mar 31, 202363-7.35%29,732,4653.28%531.99%30-9.09%1721.43%
Dec 31, 2022684.62%28,787,244-2.76%511.80%33-14-6.67%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Galileo - Biotech Innovation Fund S USD297.94K0.51%-
Protea Sectoral Hlthcare Opps P USD Acc162.26K0.28%162.26K
NT R2000 Value Index Fund - NL72.39K0.12%-10.82K
Protea Sectoral Biotech Opps IF USD Acc55.00K0.09%55.00K
BlackRock Extended Mkt Composite28.33K0.05%490.00
SSgA U.S. Extended Market Index Class I6.10K0.01%-
SSgA Russell 2000 Index Strategy6.00K0.01%-10.90K
NT R3000 Index Fund - NL2.90K0.01%-376.00
Blackstone Alternative Multi-Strategy I2.00K0.00%-200.00
SSgA U.S. Total Market Index Strategy1.76K0.00%-41.00

Recent Insider Transactions

DateNameRoleActivityValue
Apr 11, 2022AKKARAJU SRINIVAS Buy$303.07K
Apr 11, 2022Gutry Phil CHIEF BUSINESS OFFICERBuy$20.05K
Jan 24, 2022Samsara BioCapital, L.P.-Buy$200.10K
Jan 21, 2022Samsara BioCapital, L.P.-Buy$899.00K
Jan 20, 2022Samsara BioCapital, L.P.-Buy$384.50K

Insider Transactions Trends

DateBuySell
2023 Q3--
2023 Q1--
2022 Q22-
2022 Q14-
2021 Q48-

GRPH Ownership FAQ

Who Owns LENZ Therapeutics?

LENZ Therapeutics shareholders are primarily institutional investors at 54.26%, followed by 0% insiders and 0% retail investors. The average institutional ownership in LENZ Therapeutics's industry, Biotech Stocks , is 45.43%, which LENZ Therapeutics exceeds.

Does Blackrock own LENZ Therapeutics?

BlackRock is not among the top 10 institutional shareholders of LENZ Therapeutics.

Who is the top mutual fund holder of LENZ Therapeutics shares?

Galileo - Biotech Innovation Fund S USD is the top mutual fund holder of LENZ Therapeutics shares, with 0.51% of its total shares outstanding invested in 297.94K LENZ Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools